

Item 4.9 Appendix 2: Stakeholder Consultations starting and/or ending (15)– (1 June 2026 – 30 September 2026)

Policy Number	PVG approved for consultation	Title	Team	Consultation length	Consultation start date	Consultation closing date
CP33	16/04/2026	Temporary Dialysis Away from Base (DAFB) (holiday dialysis) in adults aged 18 years and above, Commissioning Policy [UPDATE]	Welsh Kidney Network	6 weeks	22/04/2026	03/06/2026
CP342	16/04/2026	Adult Kidney, Kidney-Pancreas Transplantation, Commissioning Policy [NEW]	Welsh Kidney Network	6 weeks	27/04/2026	08/06/2026
SS342	16/04/2026	Adult Kidney, Kidney-Pancreas Transplantation, Service Specification [NEW]	Welsh Kidney Network	6 weeks	27/04/2026	08/06/2026
PPS306	03/03/3036	Drug treatment for transthyretin amyloidosis with cardiomyopathy in adults	Meds Optimisation Team for Neurosciences and Long-Term Conditions	6 weeks	30/04/2026	11/06/2026
CP07	13/05/2026	Hyperbaric Oxygen Therapy, Commissioning Policy [UPDATE]	Neurosciences and Long-Term Conditions	4 weeks	13/05/2026	10/06/2026
CP87	16/04/2026	Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Commissioning Policy [UPDATE]	Cancer and Blood	6 weeks	15/05/2026	26/06/2026
SS87	16/04/2026	Lymphovenous Anastamosis (LVA) microsurgery for primary and secondary lymphoedema, Service Specification [UPDATE]	Cancer and Blood	6 weeks	15/05/2026	26/06/2026

SS276	09/06/2026	Paediatric Immunology and Infectious Diseases Service, Service Specification [NEW]	Women and Children	6 weeks	17/06/2026	29/07/2026
PPS343	09/06/2026	Nivolumab-relatlimab for untreated unresectable or metastatic melanoma in people 12 to 17 years, Policy Position Statement [NEW]	Meds Optimisation Team for Women and Children	6 weeks	10/08/2026	21/09/2026
PPS350	09/06/2026	Pegzilarginase for treating arginase-1 deficiency in people 2 years and over	Meds Optimisation Team for Cancer and Blood	6 weeks	10/08/2026	21/09/2026
PPS262	09/06/2026	Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 for children aged under 16 years who commenced treatment before the end of the managed access agreement, Policy Position Statement [NEW]	Meds Optimisation Team for Women and Children	6 weeks	21/08/2026	Consultation withdrawn on 24/08/2026
SS179	03/06/2026	Sickle Cell disorders, Thalassaemia disorder and other rare anaemias (all ages), Service Specification [UPDATE]	Cancer and Blood	4 weeks	26/08/2026	23/09/2026
PPS344	23/07/2026	Givinostat for treating Duchenne muscular dystrophy in people 6 years and over, Policy Position Statement [NEW]	Women and Children	6 weeks	09/09/2026	21/10/2026
PPS236	23/07/2026	Berotrastat for preventing recurrent attacks of hereditary angioedema for people aged 12 years and older, Policy Position Statement [UPDATE]	Cancer and Blood	4 weeks	14/09/2026	12/10/2026
PPS353	23/07/2026	Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over, Policy Position Statement [NEW]	Cancer and Blood	6 weeks	18/09/2026	30/10/2026

PPS352	23/07/2026	Emicizumab for routine prophylaxis of bleeding episodes in patients with haemophilia A without factor VIII inhibitors who have moderate disease wit a severe bleeding phenotype, Policy Position Statement [NEW]	Cancer and Blood	21/09/2026		
--------	------------	--	------------------	------------	--	--